Palmar Hyperhidrosis Pipeline Market Insights Report 2022 Featuring Key Players – Atacama Therapeutics, GlaxoSmithKline, Brickell Biotech, & Candesant Biomedical – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Palmar Hyperhidrosis – Pipeline Insight, 2022” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The “Palmar Hyperhidrosis – Pipeline Insight, 2022” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Palmar Hyperhidrosis pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

A detailed picture of the Palmar Hyperhidrosis pipeline landscape is provided which includes the disease overview and Palmar Hyperhidrosis treatment guidelines. The assessment part of the report embraces in depth Palmar Hyperhidrosis commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Palmar Hyperhidrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

Companies and academics are working to assess challenges and seek opportunities that could influence Palmar Hyperhidrosis R&D. The therapies under development are focused on novel approaches to treat/improve Palmar Hyperhidrosis.

Palmar Hyperhidrosis Emerging Drugs Chapters

This segment of the Palmar Hyperhidrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Palmar Hyperhidrosis Emerging Drugs

AT-5214: Atacama Therapeutics

AT-5214 (dexmecamylamine) is the S-enantiomer of mecamylamine, a selective inhibitor of the acetylcholine nicotinic receptor. AT-5214 is thought to inhibit the sympathetic ganglion with lessened parasympathetic side effects. Currently, it is in Phase II stage of development to treat Palmar Hyperhidrosis.

Umeclidinium: GlaxoSmithKline

Umeclidinium is a Muscarinic receptor antagonist developed by GlaxoSmithKline. It is in Phase II stage of development to treat Palmar Hyperhidrosis.

Palmar Hyperhidrosis: Therapeutic Assessment

This segment of the report provides insights about the different Palmar Hyperhidrosis drugs segregated based on the following parameters that define the scope of the report, such as:

Major Players in Palmar Hyperhidrosis

There are approx. 3+ key companies which are developing the therapies for Palmar Hyperhidrosis. The companies which have their Palmar Hyperhidrosis drug candidates in the most advanced stage, i.e. phase II include, Atacama Therapeutics.

Phases

The report covers around 3+ products under different phases of clinical development like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of: Pre-clinical and Discovery stage candidates, Discontinued & Inactive candidates, and Route of Administration.

Palmar Hyperhidrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as:

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Palmar Hyperhidrosis: Pipeline Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Palmar Hyperhidrosis therapeutic drugs key players involved in developing key drugs.

Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Palmar Hyperhidrosis drugs.

Palmar Hyperhidrosis Report Insights

• Palmar Hyperhidrosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Palmar Hyperhidrosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Players

• Atacama Therapeutics
• GlaxoSmithKline
• Brickell Biotech, Inc.
• Candesant Biomedical

Key Products

• AT-5214
• Umeclidinium
• Sofpironium bromide

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/hh73gp

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900